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http://www.retrovirology.com/content/11/1/81RESEARCH Open AccessReduced evolutionary rates in HIV-1 reveal
extensive latency periods among replicating
lineages
Taina T Immonen and Thomas Leitner*Abstract
Background: HIV-1 can persist for the duration of a patient’s life due in part to its ability to hide from the
immune system, and from antiretroviral drugs, in long-lived latent reservoirs. Latent forms of HIV-1 may also be
disproportionally involved in transmission. Thus, it is important to detect and quantify latency in the HIV-1 life cycle.
Results: We developed a novel molecular clock–based phylogenetic tool to investigate the prevalence of HIV-1
lineages that have experienced latency. The method removes alternative sources that may affect evolutionary rates,
such as hypermutation, recombination, and selection, to reveal the contribution of generation-time effects caused
by latency. Our method was able to recover latent lineages with high specificity and sensitivity, and low false
discovery rates, even on relatively short branches on simulated phylogenies. Applying the tool to HIV-1 sequences
from 26 patients, we show that the majority of phylogenetic lineages have been affected by generation-time effects
in every patient type, whether untreated, elite controller, or under effective or failing treatment. Furthermore,
we discovered extensive effects of latency in sequence data (gag, pol, and env) from reservoirs as well as in the
replicating plasma population. To better understand our phylogenetic findings, we developed a dynamic model of
virus-host interactions to investigate the proportion of lineages in the actively replicating population that have ever
been latent. Assuming neutral evolution, our dynamic modeling showed that under most parameter conditions, it
is possible for a few activated latent viruses to propagate so that in time, most HIV-1 lineages will have been latent
at some time in their past.
Conclusions: These results suggest that cycling in and out of latency plays a major role in the evolution of HIV-1.
Thus, no aspect of HIV-1 evolution can be fully understood without considering latency - including treatment, drug
resistance, immune evasion, transmission, and pathogenesis.
Keywords: HIV-1 latency, Phylogenetics, Molecular clock, False discovery rate, Dynamic modelingBackground
HIV-1 hidden in latent reservoirs is a major obstacle in
eradicating the virus, as the reservoirs may be very long-
lived [1-4]. Discontinuing antiretroviral treatment (ART)
generally results in rebound of viremia due to the activa-
tion of latent virus [5]. Thus, the eradication of HIV-1
necessarily involves reversing latency, and preventing
the activated virus from establishing new rounds of in-
fection under ART [6]. If the latent reservoir(s) could be
eradicated, ART would kill the replicating HIV-1 and* Correspondence: tkl@lanl.gov
Theoretical Biology & Biophysics, Los Alamos National Laboratory, Los
Alamos, NM 87545, USA
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article, unless otherwise stated.cure the patient [7,8]. Hence, accurately quantifying the
size of the latent reservoir is vital for guiding potential
eradication efforts and, if eradication is possible, deter-
mining when the latent reservoir is exhausted.
Recent findings suggest that latency may also be in-
volved in transmission, as latent forms appear to be pref-
erentially transmitted than more recent variants [9-12].
This implies that activated latent viruses are able to sur-
vive and propagate under immune pressure to reach suf-
ficient numbers in the plasma to be transmitted.
Because HIV-1 accumulates mutations while replicat-
ing, but not when latent, a virus lineage that has been la-
tent for some time will show a slower effective rate of
genetic evolution. Thus, latency effectively alters the rated Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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clock rates in a patient.
To detect latency in HIV-1 DNA sequence data, we
developed a phylogenetic method that identifies lineages
that have evolved less than expected under a single mu-
tation rate. Hence, we based our approach on an explicit
mechanistic hypothesis that explains overdispersion, i.e.
rate variation larger than expected from a single Poisson
process, rather than using a statistical distribution with
wider variance as has been done in generic approaches
using relaxed clocks [13].
In addition to the generation-time effect caused by la-
tency, hypermutation, recombination, and selection may
alter apparent evolutionary rates. Both positive and nega-
tive selection may affect divergence and diversity [14,15],
while activation and reintroduction of latent forms into
the replicating population may expand diversity only on
the lower tail beyond what could be described by a single
Poisson process. Our method addresses each of these ef-
fects to reveal the contribution of latency to the evolution
of HIV-1.
We first tested our latency detection method on simu-
lated phylogenies in which randomly selected branches
were affected by latency. We then applied our method
to 26 data sets, consisting of HIV-1 DNA sequence align-
ments derived from the plasma and latent reservoirs of
patients that were either untreated, successfully treated,
had experienced treatment failure or were elite control-
lers [16-19]. To understand our phylogenetic findings
from a theoretical perspective, we developed a dynamic
model of virus-host interactions under neutral evolution,
and investigated the proportion of lineages that have everA B
Figure 1 Success of phylogenetic latency detection in critical simulati
pair-wise comparisons of all taxa, testing whether the shorter lineage was s
from simulations with 100 taxa and one random branch affected by latenc
distance. Lines show moving average for general trends (flatent = 0.9–0.1, lef
(Additional file 1: Figure S2). (B) The minimum latency fraction on an affect
of non-latent taxa from the MRCA of all taxa. The height is in log10-units to
function of the mean height of non-latent taxa from the MRCA of all taxa.experienced latency. Both our phylogenetic and modeling
results suggest that latency affects the majority of phylo-
genetic lineages in most patients.
Results
Correct identification of latent lineages in simulated data
We developed a method to identify all lineages in a phyl-
ogeny that have evolved significantly less than at least
one other lineage, assuming that HIV mutates according
to a Poisson process with a single molecular clock rate
when replicating, and does not mutate when latent.
To explore the limitations of our method, we tested its
performance in critical simulations. Figure 1A shows
simulation results from random phylogenies with 100
taxa each, where one random branch was latent for a
fraction of its evolutionary time (flatent). Note that in
each simulated phylogeny, the length and position of
the latent branch may differ, and thus also the number
of taxa affected by latency (range 1—(N-1) latent taxa).
Overall, we were able to recover the lineages affected
by latency even when flatent approached small values;
for branches >0.02 subst/site and flatent > 0.4 we ob-
served >90% sensitivity (Figure 1A). Because estimating
the mean height of non-latent taxa from the MRCA of
all taxa per time point is easy in real data, we also sim-
ulated trees varying the tree height and identifying the
minimum proportion of latency in lineages that were
detected as latent to achieve 95% sensitivity (Figure 1B).
This means that, for instance, if the mean non-latent
height in a sample was 0.1 substitutions/site, we can
detect at 95% sensitivity latency periods as short as 7%
of the non-latent genetic distance, while in a populationC
on scenarios. Detection of latency-affected lineages was done by
ignificantly shorter according to a Poisson test. (A) Sensitivity results
y at flatent = 0.1–0.9 of the corresponding original non-latent genetic
t to right). Individual simulation results are shown in the Supplement
ed branch to achieve 95% sensitivity as a function of the mean height
facilitate reading short tree height performance. (C) Specificity as a
Panels B and C have loess curves fitted to show general trends.
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the affected lineages must have been latent for at least
60% of the evolutionary time. Clearly, while it is easy to
detect latency on longer branches, the effect of latency
on short branches is small and therefore also difficult
to detect. The specificity of our method was at an over-
all 98% for genetic distances at 0.1 substitutions/site,
and decreased slowly to approximately 70% at 0.25 sub-
stitutions/site (Figure 1C), a distance one rarely detects
in a within-patient single time point sample (Additional
file 1:Table S2).
As our method performs many tests, the risk of false
positives increases. While many multiple test correction
procedures have been developed, e.g., [20-22], none are
appropriate for our situation where tests are phyloge-
netically correlated and one-sided. Thus, we explored
by simulation the behavior of the false discovery rate
(FDR = FP/[TP + FP]). Figure 2 shows simulation results
from 3 million random phylogenies; the FDR had a
strong inverse relationship to the number of latent pe-
riods, and was directly proportional to both the number
of taxa and the number of detected positives (TP + FP).
The FDR was, however, only modestly affected by flatent.
When the number of taxa was small (10–20 per time
point), the FDR was <5% regardless of the number of
detected positives. As the number of latent periods
increased, the number of taxa and the number of de-
tected positives had less effect. At 5 or more latency
periods the FDR was typically <10%, and at 8 or more
latency periods the FDR was generally <5% (hairline
in Figure 2).latent periods=1
FD
R
latent periods=2
latent periods=6 latent periods=7
0 15 30 0 15 30 0
T
0.0
0.2
0.4
0.6
0.0
0.2
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Figure 2 The false discovery rate (FDR) of our phylogenetic latency d
many tests, the risk of false positives increases. This figure shows the FDR a
FDR depended strongly on the number of latency periods (panels), and on
blue = 30 taxa, purple = 40 taxa, magenta = 50 taxa, and red = 60 taxa. Each
flatent = 0.5–0.9. Means were calculated when ≥50 observations occurred atReduced evolutionary rates identify latency in the
majority of lineages
Next, we applied our phylogenetic latency detection
method to real data from 26 longitudinally sampled pa-
tients, including both HIV-1 sequences from the actively
replicating plasma population and latently infected rest-
ing CD4+ T cells [16-19]. Because reduced evolutionary
rates may be the result of other processes in addition to
latency (which causes generation-time effects), i.e., artifi-
cially long reference taxa due to hypermutation or re-
combination, or selection making some lineages evolve
faster or slower than others, we first removed hypermu-
tants and potential recombinants that could bias our re-
sults (Table 1). To remove the potential bias that might
cause rate differences due to selection, we analyzed phy-
logenies based on 3rd codon positions only. First, the re-
sults based on 3rd codon positions were very similar to
the results based on all positions (compare Table 1 and
Additional file 1: Table S1). Second, as we detected slightly
more recombinants and fewer latents in all positions, this
suggests that some potential recombinants that we iden-
tified based on all positions probably were in fact misiden-
tified selection effects. Note that it is well known that
selection and recombination are confounding factors diffi-
cult to discriminate [23-25]. As our goal here was to re-
move both selection and recombination effects in order to
see the effects of latency, however, it did not matter in
which way we removed them.
To evaluate the potential of overestimating latency
due to statistical effects, we estimated the total number
of FP’s per patient (Table 1) based on the inferred FDRlatent periods=3 latent periods=4 latent periods=5
latent periods=8 latent periods=9
15 30
P+FP
0 15 30 0 15 30
latent periods=10
etection method. Because our latency detection method performs
s a function of the total number of positives detected (TP + FP). The
the number of taxa compared (lines); cyan = 10 taxa, green = 20 taxa,
line shows the mean of 50,000 simulated random phylogenies at
any TP + FP level. The hairline shows FDR = 0.05.
Table 1 Summary of patient data and latency results based on 3rd codon positions
Patient ID Patient type Gene L Time points No. taxa H R No. (%) latent taxa detected
Total Plasma Reservoir FP
K-B U env 714 3 49 1 0 43 (87.8) 24 (85.7) 19 (90.5) 0.7
K-G U env 729 3 49 0 0 38 (77.6) 18 (62.1) 20 (100) 1.0
O-1 E gag 1386 3 20 0 0 16 (80.0) 2 (40.0) 14 (93.3) 0.8
O-7 E gag 1271 9 53 1 3 27 (50.9) 26 (55.3) 1 (16.7) 0.8
O-8 E gag 1298 7 101 0 0 60 (59.4) 15 (27.8) 45 (95.7) 4.7
O-9 E gag 1271 5 50 2 0 32 (64.0) 3 (15.0) 29 (97.0) 0.6
M-1 F pol 985 1 22 0 0 12 (54.5) 6 (60.0) 6 (50.0) 0.1
M-96 F pol 637 2 19 0 0 0 (0.0) 0 (0.0) 0 (0.0) 0
M-100 F pol 637 1 16 0 0 4 (25.0) 2 (40.0) 2 (18.2) 0.3
M-102 F pol 637 3 108 0 1 59 (54.6) 12 (42.8) 47 (58.8) 0.9
M-105 F pol 637 3 54 0 0 48 (87.3) 24 (82.8) 24 (92.3) 0.1
M-110 F pol 637 1 12 0 0 11 (91.7) 5 (83.3) 6 (100) 0.1
M-112 F pol 637 1 25 0 0 18 (72.0) 5 (55.6) 13 (81.3) 0.1
M-122 F pol 637 1 14 0 0 7 (50.0) 0 (0.0) 7 (87.5) 0.7
M-126 F pol 637 1 18 0 0 5 (27.8) 4 (66.7) 1 (0.08) 0.5
M-127 F pol 985 1 14 0 0 8 (57.1) 4 (100) 4 (40.0) 0.1
M-137 F pol 637 2 33 0 0 17 (51.5) 1 (0.06) 16 (94.1) 0.1
M-138 F pol 985 1 11 0 0 0 (0.0) 0 (0.0) 0 (0.0) 0
B-113 T pol 546 10 47 0 0 33 (70.2) 11 (47.8) 22 (91.7) 0.1
B-134 T pol 546 5 76 0 0 54 (71.1) 1 (14.3) 53 (76.8) 1.6
B-136 T pol 546 10 110 0 0 50 (45.5) 5 (11.4) 45 (68.2) 20
B-139 T pol 546 10 126 0 0 88 (69.8) 18 (41.9) 70 (84.3) 4.9
B-147 T pol 546 10 132 0 0 112 (84.8) 28 (65.1) 84 (94.4) 2.5
B-148 T pol 546 4 152 0 0 129 (84.9) 7 (50.0) 122 (88.4) 4.5
B-154 T pol 546 18 337 0 0 154 (45.7) 77 (35.2) 77 (65.3) 5.9
B-154 T env 306 3 64 3 0 50 (78.1) 30 (71.4) 20 (90.9) 1.3
Footnotes: Patient type, U = untreated, E = elite controller, F = failed treatment, T = successful treatment; L = original sequence length of all codon positions;
H = number of hypermutants removed; R = number of recombinants removed; No. taxa = number of taxa after H and R removal; FP = estimated number of false
positives. Additional results in Additional file 1: Tables S1 and S2.
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of FP’s was very small in all patients (on average 2/pa-
tient), except B-136 because of a high FDR at time point
25 weeks (0.3 FP/[TP + FP]). Furthermore, to facilitate
comparison of the real patient data to our phylogenetic
simulations (Figure 1B), we determined the mean height
of non-latent taxa from the MRCA of all taxa per time
point (Additional file 1: Table S2). Typically, the within-
patient height in a sample was 0.054 substitutions/site,
which corresponds to correctly identifying lineages that
have been latent for at least 15% of the height at a sensi-
tivity of 95%, and nearly 100% specificity. The variance
was large, however, with a standard deviation of 0.046
and range of 0.001—0.24 substitutions/site, emphasizing
that there are large patient and virus specific differences
in the observed evolutionary rates.Overall, regardless of whether the patient was un-
treated, successfully treated, had experienced treatment
failure, or was an elite controller, the generation-time ef-
fects of latency was detected in the majority of phylo-
genetic lineages (Table 1). The overall mean fraction of
latent lineages across all patients was 59% (57% cor-
rected for estimated FP). More specifically, we found
latency in 45% of plasma-derived virus (the actively re-
plicating population at sampling), and 68% of latent re-
servoirs consisting of resting CD4+ cells. Finding more
lineages affected by generation-time effects in the latent
reservoir confirms that our detection method picks up
the relevant signal. The fact that we find a high fraction
of lineages affected by generation-time effects in the
plasma suggests that activated latent viruses are able to
compete against more recent variants that have evolved
Immonen and Leitner Retrovirology 2014, 11:81 Page 5 of 11
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The proportion of plasma-derived virus measurably af-
fected by latency was 42% for treated patients, 82% for
untreated patients, 35% for elite controllers, and 44% for
patients with treatment failure, not differing significantly
between groups (p = 0.24, Kruskal-Wallis rank sum test).
Latency occurs throughout infection
Figure 3 shows representative examples of serially sam-
pled phylogenies based on 3rd codon positions only of
each patient type. All patient trees are shown in the Sup-
plement (Additional file 1: Figure S1). Clearly, the major-
ity of taxa have been affected by significant reductions in
their evolutionary distances (filled symbols). The HIV-1
phylogeny from patient K-G shows that shortly after in-
fection, the difference in how far lineages have evolved is
negligible. This makes sense, as cycling through latency
should have a small effect on the number of mutationsFigure 3 Latency detection in HIV-1 phylogenies. To avoid effects of se
reconstruction and latency detection. Latency was detected in an untreate
(B-139), and in a patient with failed treatment (M-105). These are represent
in the online supplementary materials (Additional file 1: Figure S1). Taxa are
virus. Filled symbols indicate significant reduction in genetic distance (circle
potential recombinants, omitted from latency detection. Unlabelled ingrou
cells. Color indicates time since 1st sample of patient. Patient K-G was roote
were rooted by an outgroup (HIV-1 HXB2, unlabelled). The circled numbersearly in infection; few mutations could have accumulated
when not many replication cycles have occurred. In pa-
tients K-B and K-G (untreated patients), the first time
point samples were used to root the trees. At later time
points, in K-G and all other patients, latency had af-
fected most lineages. All patients show continuous evolu-
tion, interrupted by clonal expansions of latency-affected
taxa, where plasma derived virus are identical to reservoir
viruses (e.g., circle-1 in Figure 3). Notably, while viruses
derived from reservoirs have often evolved less, both res-
ervoir and plasma viruses show effects of latency-reduced
evolution in many patients.
Dynamic model predictions agree with phylogenetic
findings
To independently investigate our phylogenetic findings,
we expanded a previous dynamic pathogen-host model
[26,27] by tracking viruses that have cycled through alection, only 3rd codon DNA positions were used for phylogenetic
d patient (K-G), an elite suppressor (O-9), a successfully treated patient
ative patients of each group in Table 1. All 26 patient trees are shown
labeled P for plasma-derived virus and R for resting CD4+ T cell pro-
s p < 0.05; squares p < 0.01; triangles p < 0.001). Crossed circles indicate
p taxa indicate additional sequences from neither plasma nor resting
d at 1st sample close to PHI (unlabeled taxa), and the other patients
are observations of interest discussed in the text.
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HIV-1). The dynamic modeling suggests that under neu-
tral evolution, the relatively small numbers of activated
latent viruses will propagate in the plasma so that most
HIV-1 lineages in the replicating population have been
latent at some time in their past under most parameter
value combinations (Figure 4A). Not surprisingly, the
fraction of infections resulting in latency η had the lar-
gest effect on the proportion of ever-latent HIV-1 inDeposit fraction =1e
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infected cells were never activated, latency would effec-
tively be a dead end with no effect on the plasma po-
pulation. At intermediate values, however, we observed
massive fractions of ever-latent virus. Interestingly, the
reservoir half-life had a negligible effect on the fraction
of ever-latents. Regardless of parameter values, the frac-
tion of ever-latents grew slowly over time after initial es-
tablishment, implying that 1) latency deposition startsDeposit fraction =1e−07
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expands its potential to influence HIV-1 adaptation over
time, both by concentration and mutational spectrum.
Assuming neutrality, however, ignores immune selec-
tion and fitness differences between ever- and never-
latent viruses. Therefore, we introduce a constant fitness
cost (1-εE) on ever-latent lineages, making it more diffi-
cult for them to survive. Figure 4B shows that the pro-
portion of ever-latent lineages in the replicating
population corresponds to our phylogenetic results only
when there is a large contribution of activated latent vi-
ruses every generation. For example, the population
reaches >50% latently affected lineages in 10 years when
aL >10
−2, η >10−4, and 1-εE = 0.01 with a reservoir half-
life of 10 months.
When introducing drug treatment in the neutral
model, with an efficacy at εE = εN = 0.85, the ever-latent
fraction immediately increased to dominate the plasma
virus population, regardless of η, aL, and δL values.
Discussion and conclusions
We identified high proportions of lineages affected by la-
tency in both the replicating plasma population and the
latent reservoir in all patient types. Our findings suggest
that HIV-1 cycles in and out of latent reservoirs regard-
less of patient treatment history. It is well known that
among the few viruses that can be detected in patients
under successful treatment, many have been reactivated
from the latent pool [3,28,29]. Hence, we expected to
find a notable proportion of lineages affected by latency
in the plasma of treated patients; while this was true,
however, the latency-affected proportion was also high
in the plasma of untreated patients. This observation
emphasizes that latency occurs regularly in the HIV-1
life cycle.
Our phylogenetic method shows that there are more
lineages with reduced divergence in the reservoir than in
the actively replicating population. This supports that
we indeed find true latent lineages with our detection
method. However, we did not find a perfect concordance
in viruses from the plasma being non-latent and those
from the reservoir being latent (virus with significant
reduction in divergence). This is due to the fact that
reservoir-derived viruses may have been deposited as
recently as the day before sampling, while conversely,
viruses in the plasma may have been activated re-
cently. Therefore, binary classification based on where
sequences come from (plasma vs. reservoir) is rather
crude and ignores the history of the virus in either
compartment, while our method gives a quantitative
and continuous measure of latency periods regardless
of compartment.
Similarly, although typically only small numbers of
reactivated latent virus appear in the plasma populationafter substantial reductions in viremia due to effective
antiviral therapy, this does not imply that only few viral
lineages have cycled through the latent pool. Under neu-
trality, our dynamic model shows that even when the
fraction of infected cells that become latent is small, and
the activation rate of latently infected cells is low, the
proportion of viral lineages that have ever been latent in
the plasma is large. Analogously, a small stream may
feed a large lake that also has a small outflow. If the lake
was quickly evacuated, the small stream could not refill
the lake immediately. Thus, the input has very little to
do with the size of the holding tank (lake or viral load).
We also show that introducing a constant fitness cost to
ever-latent virus will make it much harder for such virus
to survive. However, assuming a constant fitness cost on
ever-latent viruses is not realistic for two main reasons:
1) ever-latent virus evolve, and can thus escape from im-
mune pressure in time; 2) ever-latent virus may periodic-
ally have similar fitness as never-latent virus because the
immune response evolves and changes over time. For
example, when new antibody responses evolve, never-
latent viruses will have reduced fitness until they acquire
escape mutations. The ODE model we use here cannot
include such effects.
Note that our phylogenetic detection method is a con-
servative estimate as we only compare taxa sampled at
the same time, avoiding extrapolations between sam-
plings, and likely underestimating the full impact of la-
tency on branch lengths. Similarly, as rooting may affect
latency detection in samples close to the root, we avoid
potential errors in nearby samples by only considering
each sampling time separately. Furthermore, the method
considers relative rather than absolute latency; if latency
is detected, it is with respect to at least one other se-
quence, which is by definition classified as non-latent.
However, the reference taxa itself may be latent, in which
case all relatively less divergent taxa must also have
been latent. In fact, the prevalence of sequences from
the latent reservoir with no significant divergence re-
duction (e.g., circle-2 in Figure 3) suggests that we may
consistently underestimate latency. As the dynamic model
considers absolute rather than relative latency the pre-
dicted fraction of ever-latent lineages is generally higher
than identified in patient data by our phylogenetic detec-
tion method.
As latent lineages are detected relative to the reference
taxa, it is crucial that the latter are placed correctly
in the phylogeny to avoid overestimating latency due
to artificially long reference taxa. In addition to hy-
permutation, which can elongate branches, within-patient
recombination may also result in exaggerated branch
lengths. A recombinant may be placed basal in a phyl-
ogeny with a short branch length, or it may sit near one
of the parent strains, with mutations from the other
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creasing the branch length. As detailed in Materials &
Methods, we removed any reference taxa identified as
potential recombinant or hypermutated taxa to prevent
overestimating latency. To avoid effects of selection
causing significant deviations in our latency detection,
we analyzed 3rd codon positions as most selection pres-
sure is asserted on the protein level. While more sophis-
ticated methods to analyze codons and codon positions
are available [30-32], interestingly, however, we found
that the identification of latent lineages was nearly the
same when using all codon positions (compare Table 1
and Additional file 1: Table S1). This might be because
immune selection is not strong enough to cause signifi-
cantly different rates of evolution in coexisting lineages
as all virus that survive to be detected have been under
similar selection pressure, and over shorter time periods
(<3 years) within-host evolution is consistent with neu-
trality [15]. Thus, the main contribution to HIV-1 rate
differences stems from compartmentalized generation-
time effects in latent reservoirs that slow down the
evolution.
From the clinical perspective, latency is not a problem
only relevant in patients with drug failure, but rather an
integral part of the HIV-1 life cycle, expanding the evo-
lutionary adaptation potential of the virus. Interestingly,
Ho et al. recently showed that the latent reservoir may
be up to 60-fold greater than previously estimated [33],
further corroborating the central role of latency in infec-
tion dynamics. The recent findings suggesting preferen-
tial transmission of latent viruses, which necessitates a
prevalence of latent lineages in the plasma, are also in
line with our results [9-12]. From a biological perspec-
tive, latency explains the overdispersion in the molecular
clock, previously observed but poorly understood. Thus,
latency mechanistically explains evolutionary rate vari-
ation and is fundamental to understanding clinical out-
comes related to pathogenesis and treatment.
Methods
Patient data
The representative data sets in Table 1, acquired from
the Los Alamos HIV sequence database (http://www.hiv.
lanl.gov/), consist of serially sampled sequence data from
the gag, pol, or env genes of a total of 26 patients that
were either untreated (n = 2) [18], successfully treated
(n = 8) [17], had undergone treatment failure (n = 12)
[19], or were elite suppressors (n = 4) [16]. The untreated
patients were followed from primary HIV-1 infection
(PHI), where the first sample was taken within a week of
symptomatic PHI. These patients were still untreated at
follow-up sampling 58—79 months later. Successfully
treated patients consisted of infected adults with pro-
longed suppression of viremia to <50 copies/ml on astable HAART regimen (mean duration of suppression
prior to enrollment, 34 months: range, 11 to 79 months).
For the patients with treatment failure, 11 of the 12 pa-
tients were on HAART at time of sampling, had been on
current therapy for a mean of 9 months (0.5 to 20
months), and had been failing their current therapy for a
mean of 7 months (0.5 to 20 months). All patients had a
history of prior treatment failure with a mean time of
5 years of viral replication in the presence of antiretro-
viral therapy (range 8 to 128 months). Patient M-1 was
not under treatment during sampling. The elite suppres-
sors have maintained control of HIV-1 without HAART
for several years, with mostly normal CD4+ T cell counts
and plasma HIV-1 RNA levels below the limit of detec-
tion of clinical assays (<50 copies/ml). Additional file 1:
Tables S1 and S2 present additional and detailed infor-
mation about each patient and the longitudinal samples
per patient.
We included patients with at least 10 sequences iso-
lated from plasma and resting CD4 cells in the analysis.
We did not distinguish whether sequences from resting
cells were induced or replication-competent. Due to low
viral loads, Bailey et al. [17] sampled the plasma of suc-
cessfully treated patients every two to three days, with
the samples generally consisting of only a few sequences.
As HIV-1 sequences sampled two weeks apart or less
show no significant evolution [15], we merged sequences
sampled within one week into the same time point. The
accession numbers for the data sets are AF349770-
AF349906, GU993311-GU993518, DQ391282- DQ392955,
and AY964187-AY964601, respectively.Phylogenetic reconstruction
We used the multiple sequence alignment software
MAFFT version 7 [34] and GeneCutter (http://www.hiv.
lanl.gov/) to create in-frame sequence alignments for
each patient, allowing analyses of separate codon posi-
tions. Hypermutants were removed using the APOBEC
context pattern test Hypermut 2.0 [35]. As each un-
treated patient was sampled shortly after PHI, we used
the consensus sequence at the first time point, made by
Consensus Maker v2.0.0 (http://www.hiv.lanl.gov/), as
the reference sequence against which all sequences were
compared to identify hypermutants. For all other pa-
tients, we used the full sequence alignments to make the
respective consensus sequences.
Latency detection was first applied to the N taxa at the
first time point, and the Phi-test was performed to iden-
tify potential recombination [36]. If φ ≥ 0.05, the set of
sequences had no recombination signal, and the next
time point was considered. If φ < 0.05, taxa were re-
moved sequentially with replacement until the recom-
bination signal in the alignment disappeared, i.e., each
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time, the Phi-test run, and the removed sequence re-
placed. If the φ-score become insignificant (φ ≥ 0.05)
when a reference taxon was removed, it was removed
from the original time-point alignment, and the latency
test and the recombination identification procedure run
again. If the recombination signal was lost with the re-
moval of a non-reference taxa, the next time point was
considered. If the recombination signal was not lost, the
procedure was repeated for the alignment of N − 1 se-
quences with the highest φ-score. The latency detection
and recombination identification tests were performed
sequentially until φ ≥ 0.05, and no potentially recombin-
ant reference taxa remained, before moving to the next
time point. We developed the phylogenetic latency de-
tection and recombination identification methods in R
version 3.0.1 [37]. A similar algorithm using the Phi-test
to identify/remove potential recombinants was previ-
ously developed by Salemi et al. [38].
After identifying and removing hypermutant and re-
combinant reference taxa, we inferred the phylogeny of
each patient using PhyML 3.0 [39], with a general-time-
reversible model that included rate variation among sites
(GTR + Γ + I). As ancient viruses hiding in the latent res-
ervoir can become activated late in the infection, rooting
a phylogeny based on the sequences sampled at the first
time point leads to the correct time structure only if the
time point is early enough in the infection for latency to
have had a negligible effect. As the untreated patients
were sampled shortly after PHI, we used the most recent
common ancestor (MRCA) of the sequences in the first
time point to root each phylogeny. As the patients in the
elite suppressor, treatment, and treatment failure cat-
egories were not sampled early in the infection, we
rooted each phylogeny based on an outgroup (HIV-1
strain HXB2).
Phylogenetic latency detection
HIV-1 lineages do not evolve independently; rather, they
share much of their evolutionary history. To circumvent
this dependency, we investigated all possible taxonomic
sequence pairs, per time point, tracing their evolution
back to the corresponding most recent common ances-
tor (pair-MRCA). In each such pair, the two resulting
lineages will have independent mutational information,
allowing us to calculate the Poisson probability p of ac-
cumulating the number of mutations observed on the
shorter lineage dShort, given the evolutionary rate of the
longer lineage dLong. Thus, we define latency when the
shorter lineage indicated a Pr λ
k
k! e
−λ
 
≤0:05 , where λ =
dLong * L and k ≤ dShort * L with sequence length L. For
each latent taxon, we identified the corresponding refer-
ence taxon, defined as the longer lineage in the pair inwhich the latent signal was the strongest. Note that la-
tent lineages can be identified in many pairwise compar-
isons. While this gives robustness to the test, the many
tests performed also increases the risk of false positive
test results. Thus, we controlled for the false discovery
rate (FDR), informed by simulations as follows.Phylogenetic power and precision simulations
To understand the limitations of our method, we deter-
mined the sensitivity (correct identification of latent lin-
eages; defined as true positives/[true positives + false
positives] (TP/[TP + FP)) and specificity (correct identifi-
cation of non-latent taxa; defined as true negatives/[true
negatives + false negatives] (TN/[TN + FN])) of detecting
latent taxa as a function of how much latency reduced a
particular branch length in a phylogenetic tree, called
flatent, and the original length of the latency affected
branch. For this we simulated data by generating 90,000
random phylogenies consisting of 100 taxa each with an
expected height of 0.1 substitutions/site and a sequence
length of 1000 nt, reducing the length of a randomly
chosen branch by a fraction flatent = 0.1—0.9 of its ori-
ginal length. We also evaluated sensitivity and specificity
as a function of divergence among lineages where la-
tency had not affected the evolutionary rate by simu-
lating 292,500 random trees at 0.001—0.3 substitutions/
site tree height and reducing a random branch at
flatent = 0.1—0.9. Note that all of these simulations
assumed a single latency period per tree.
Because we perform many tests, we also investigated
by simulation the false discovery rate (FDR), defined
as FP/[TP + FP]. To estimate the FDR, we varied the
number of taxa in a sample (range 10—60), flatent (range
0.5—0.9), and the number of latent periods (range 1—
10). At each parameter combination we simulated
10,000 random trees, totaling 3,000,000 simulations, to
estimate the FDR relevant to our testing conditions. In
addition, we simulated the FDR on 50,000 trees for each
patient sample (1—18 time points/patient), adjusting for
the precise number of taxa and estimated minimum
number of independent latency periods, totaling
7,800,000 patient specific simulations (Additional file 1:
Table S2).Dynamic model
To examine the impact of latency on the overall evolu-
tion of HIV-1 within a patient, we extended a basic
model of HIV-1 latency developed by Rong et al. [26,27]
to explicitly account for never-latent and ever-latent
virus lineages. Ever-latent lineages consist of viruses that
have cycled through a latent reservoir at some time in
their past, while those classified as never-latent have al-
ways been actively replicating. The model is described
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(ODEs):
dT
dt
¼ λ−δTT− 1−εEð ÞkTVE− 1−εNð ÞkTVN
dIN
dt
¼ 1−εNð Þ 1−ηð ÞkTVN−δI IN
dVN
dt
¼ NδI IN−cVN
dIE
dt
¼ 1−εEð Þ 1−ηð ÞkTVE−δI IE þ aLL
dVE
dt
¼ NδI IN−cVE
dL
dt
¼ 1−εEð ÞηkTVE þ 1−εNð ÞηkTVN−aLL−δL
where T are uninfected CD4+ T cells , VN and VE the
never-latent and ever-latent virus concentrations in
plasma, respectively, IN and IE cells infected with never-
latent and ever-latent virus, and L are resting latently in-
fected cells.
Uninfected cells proliferate at rate λ, are infected ac-
cording to the laws of mass action at rate k, and die at
rate δT, while infected cells die at rate δI. The fraction of
infections resulting in latency is η, while latent cells are
activated at rate aL to become productively infected
cells. Infected cells have a burst size of N and plasma
virus decay at rate c. The fitness effect of the immune
response reduces infection by a fraction of εN for never-
latent lineages and εE for ever-latent lineages. To investi-
gate the effects of anti-viral drugs we set εE = εN = 0.85.
We did not explicitly model the regeneration of latently
infected cells [26,27], but rather calibrated the net
growth rate δL of the latent cells to achieve a desired half
life Hlife of the latent reservoir for a given activation rate,
namely, δL = ln(2)/Hlife-aL. As the half life has been es-
timated to range between 6 months [40,41] and 44
months [42,43], we chose a broad range between 1 and
100 months.
The other parameters and variables used in the model
are described in Table S2. As in [27], we set the initial
conditions for uninfected CD4 T cells, T, and never-
latent virus,VN, to be 10
6 cells/ml [27] and 50 RNA cop-
ies/ml, respectively. In addition we assumed that there
were no productively infected cells, resting latently in-
fected cells, or virus from ever-latent lineages at t = 0.
The model was solved numerically using the R package
deSolve [44].Additional file
Additional file 1: Figure S1. 26 individual patient trees. Figure S2.
Raw sensitivity simulation results. Table S1. Patient data and results
based on all codon positions. Table S2. Detailed results based on 3rd
codon positions. Table S3. Dynamic model parameters and variables.Competing interests
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